Shares of Advaxis plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated their collaboration on an immuno-oncology program.
Celltrion Inc. and Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration approved Herzuma (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to Herceptin (trastuzumab).
In men with localized prostate cancer discovered because they had symptoms or noticed during a work-up for another medical problem, radical prostate surgery leads to an average of three extra years of life compared to a “watchful waiting” approach, researchers say.
Generon Presents Positive Phase III Results Of F-627 In Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Generon BioMed Holding Ltd. announced at the annual San Antonio Breast Cancer Symposium (SABCS) positive results from a placebo-controlled trial with F-627, a recombinant human Granulocyte Colony Stimulating Factor protein, designed using Generon’s Dikine technology platform.
AstraZeneca’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head & neck cancer.
Roche Holding AG’s Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.
AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.
Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology identified a nano-scaled DNA signature that seems to be common to all cancers.
Swiss group Roche Holding AG said the company’s Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals’ revenues.
Johnson and Johnson said a combination therapy containing the company’s blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.